Drug Profile
Research programme: Alzheimer's disease therapeutics - Allele Biotechnology and Pharmaceuticals
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Allele Biotechnology and Pharmaceuticals
- Class Antidementias; Single-domain antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Alzheimer's-disease in USA